Supplemental Table 2: Serious Adverse Event Summary

Serious Adverse Event (reported for the duration of the study)	**$RV5_{mp}$** (N=509)		**RV5** (N=505)	
	n	(%)	n	(%)
Anal abscess	1	(0.2)	1	(0.2)
Bronchiolitis	3	(0.6)	1	(0.2)
Bronchitis	0	0.0	1	(0.2)
Cellulitis	1	(0.2)	0	0.0
Gastroenteritis viral	0	0.0	1	(0.2)
Head injury	0	0.0	1	(0.2)
Hypersomnia	1	(0.2)	0	0.0
Intussusception	2	(0.4)	0	0.0
Laryngitis	1	(0.2)	0	0.0
Loss of consciousness	1	(0.2)	0	0.0
Parainfluenzae virus infection	1	(0.2)	0	0.0
Pneumonia	2	(0.4)	0	0.0
Pyelonephritis	1	(0.2)	1	(0.2)
Pyelonephritis acute	0	0.0	1	(0.2)
Pyrexia	1	(0.2)	0	0.0
Respiratory syncytial virus bronchiolitis	1	(0.2)	0	0.0
Respiratory tract infection viral	0	0.0	1	(0.2)
Restlessness	0	0.0	1	(0.2)
Septic shock	1	(0.2)	0	0.0
Subcutaneous haematoma	0	0.0	1	(0.2)
Umbilical hernia	0	0.0	1	(0.2)
Upper respiratory tract infection	1	(0.2)	0	0.0
Urinary tract infection	1	(0.2)	1	(0.2)
Viral infection	1	(0.2)	1	(0.2)

N = Number of subjects in population with follow-up

n = Number of subjects in each category

Every subject is counted a single time for each applicable row and column